...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in hematology. >A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes
【24h】

A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes

机译：粒细胞菌落刺激因子的新型治疗方案与急性髓性白血病和骨髓增强综合征的老年患者的超低剂量去蛋白和低剂量红细胞红宝石合并

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) unfit for intensive chemotherapy are emergent for suitable treatment strategies. Hypomethylating agents and low-dose cytarabine have generated relevant benefits in the hematological malignancies over recent decades. We evaluated the efficacy and safety of the novel treatment regimen consisting of ultra-low-dose decitabine and low-dose cytarabine, with granulocyte colony-stimulating factor (G-CSF) in this population of patients. Methods and materials: Patients aged more than 60?years with newly diagnosed AML/MDS were enrolled to receive therapy combined of 300?μg subcutaneously per day for priming, decitabine 5.15–7.62?mg/m 2 /d intravenously and cytarabine 15?mg/m 2 /d twice a day subcutaneously and G-CSF for consecutive 10?days every 28?days. The study enrolled 28 patients unfit for standard intensive chemotherapy. The median age of patients was 68?years (range 60–83?years) and 20 (71.4%) patients harbored AML. The primary outcome was to evaluate overall response rate. Results: Overall, this novel ultra-low-dose treatment regimen was well tolerated, with 0% of both 4- and 8-week mortality occurrence. Objective response rate (CR? ?CRi? ?PR in AML and CR? ?mCR? ?PR in MDS) was 57.1% after the first treatment course. Responses of hematologic improvement (HI) aspect were achieved in 18 of 28 (64.3%) patients, 11 (39.3%), 12 (42.9%), and eight patients (28.6%) achieved HI-E, HI-P, HI-N, respectively. Conclusions: Untreated elderly with AML/MDS were well tolerated and benefited from this novel ultra-low-dose treatment regimen.
机译：背景：急性髓性白血病（AML）和髓细胞增强综合征（MDS）的年龄较大的患者因适当的治疗策略而不合适的强化化疗。低甲基化试剂和低剂量的溶细胞标记在近几十年来的血液恶性肿瘤中产生了相关的益处。我们评估了由超低剂量去Deateabine和低剂量的细胞甘油链组成的新型治疗方案的疗效和安全性，在该患者的粒细胞菌刺激因子（G-CSF）中。方法和材料：60多年来的患者患有新诊断的AML / MDS的患者每天纳入治疗300μg的治疗，静脉注射5.15-7.62〜15-7.62〜15-7.62毫克/ m 2 / d / m 2 / d每天两次皮下和G-CSF连续10个？每28天的天数。该研究注册了28名患者不适合标准的强化化疗。患者的中位年龄为68岁（范围60-83岁），20名（71.4％）患者患有AML。主要结果是评估整体反应率。结果：总体而言，这种新型超低剂量治疗方案耐受良好，占4-周和8周死亡率的0％。客观反应速率（Cr？α？CRI？α？在AML和Cr？MCR中的PR？？MDS中的MDS）在第一次治疗过程后为57.1％。血液学改善（HI）方面的反应于28例（64.3％）患者，11名（39.3％），12（42.9％）和8名患者（28.6％）达到Hi-E，Hi-P，HI-分别。结论：AML / MDS未经处理的老年人耐受良好，并受益于此新颖的超低剂量治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号